Your browser doesn't support javascript.
loading
Experiencia clínica con 53 trasplantes cardiacos consecutivos / Clinical experience with 53 consecutive heart transplants
Villavicencio, Mauricio; Rossel, Víctor; Larrea, Ricardo; Peralta, Juan Pablo; Larraín, Ernesto; Sung Lim, Jong; Rojo, Pamela; Gajardo, Francesca; Donoso, Erika; Hurtado, Margarita.
  • Villavicencio, Mauricio; Instituto Nacional del Tórax. Santiago. CL
  • Rossel, Víctor; Instituto Nacional del Tórax. Santiago. CL
  • Larrea, Ricardo; Instituto Nacional del Tórax. Santiago. CL
  • Peralta, Juan Pablo; Instituto Nacional del Tórax. Santiago. CL
  • Larraín, Ernesto; Instituto Nacional del Tórax. Santiago. CL
  • Sung Lim, Jong; Instituto Nacional del Tórax. Santiago. CL
  • Rojo, Pamela; Instituto Nacional del Tórax. Santiago. CL
  • Gajardo, Francesca; Instituto Nacional del Tórax. Santiago. CL
  • Donoso, Erika; Instituto Nacional del Tórax. Santiago. CL
  • Hurtado, Margarita; Instituto Nacional del Tórax. Santiago. CL
Rev. méd. Chile ; 141(12): 1499-1505, dic. 2013. ilus, graf
Article in Spanish | LILACS | ID: lil-705567
ABSTRACT

Introduction:

Heart transplantation is the therapy of choice for advance heart failure. Our group developed two transplant programs at Instituto Nacional del Tórax and Clínica Dávila. We report our clinical experience based on distinctive clinical policies. Patients and

Methods:

Fifty-three consecutive patients were transplanted between November 2008 and April 2013, representing 51% of all Chilean cases. Distinctive clinical policies include intensive donor management, generic immunosuppression and VAD (ventricular assist devices) insertion.

Results:

Ischemic or dilated cardiomyopathy were the main indications (23 (43%) each), age 48 ± 13 years and 48 (91%) were male. Transplant listing Status IA 14 (26%) (VAD or 2 inotropes), IB 14 (26%) (1 inotrope) and II25 (47%) (no inotrope). Mean waiting time 70 ± 83 days. Twelve (24%) were transplanted during VAD support (median support 36 days). Operative technique orthotopic bicaval transplant with ischemia time 175 ± 54 min. Operative mortality 3 (6%), all due to right ventricular failure. Re-exploration for bleeding 2 (4%), stroke 3 (6%), mediastinitis 0 (0%), pneumonia 4 (8%), and transient dialysis 6 (11%). Mean follow-up was 21 ± 14 months. Three-year survival was 86 ± 6%. One patient died of Pneumocystis jirovecii pneumonia and the other died suddenly (non-compliance). Freedom from rejection requiring specific therapy was 80 ± 7% at 3 years of follow-up. Four hundred eighty four endomyocardial biopsies were done 11 (2.3%) had 2R rejection. All survivors are in NYHA (New York Heart Association) functional class I and all but one have normal biventricular function.

Conclusion:

Mid-term results are similar to those reported by the registry of the International Society for Heart and Lung Transplantation. This experience has a higher proportion of VAD support than previous national series. Rejection rates are low in spite of generic immunosuppression.
Subject(s)


Full text: Available Index: LILACS (Americas) Main subject: Heart Transplantation / Graft Survival / Heart Failure Type of study: Observational study / Prognostic study / Risk factors Limits: Adult / Female / Humans / Male Country/Region as subject: South America / Chile Language: Spanish Journal: Rev. méd. Chile Journal subject: Medicine Year: 2013 Type: Article Affiliation country: Chile Institution/Affiliation country: Instituto Nacional del Tórax/CL

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Index: LILACS (Americas) Main subject: Heart Transplantation / Graft Survival / Heart Failure Type of study: Observational study / Prognostic study / Risk factors Limits: Adult / Female / Humans / Male Country/Region as subject: South America / Chile Language: Spanish Journal: Rev. méd. Chile Journal subject: Medicine Year: 2013 Type: Article Affiliation country: Chile Institution/Affiliation country: Instituto Nacional del Tórax/CL